Timur Ivannikov
Stock Analyst at Cantor Fitzgerald
(2.10)
# 2,959
Out of 5,115 analysts
9
Total ratings
50%
Success rate
8.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Timur Ivannikov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics | Reiterates: Overweight | $8 | $1.62 | +393.83% | 1 | Jun 27, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $28 → $25 | $27.05 | -7.58% | 1 | May 14, 2025 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $5 | $2.28 | +119.30% | 2 | Mar 7, 2023 | |
| ANAB AnaptysBio | Downgrades: Market Perform | n/a | $47.41 | - | 1 | Jan 6, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $22 | $3.48 | +532.18% | 1 | Jul 8, 2022 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $112 → $114 | $22.58 | +404.87% | 1 | Mar 1, 2022 | |
| CBIO Crescent Biopharma | Downgrades: Market Perform | n/a | $9.59 | - | 2 | Nov 15, 2021 |
ProQR Therapeutics
Jun 27, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.62
Upside: +393.83%
Pharvaris
May 14, 2025
Maintains: Overweight
Price Target: $28 → $25
Current: $27.05
Upside: -7.58%
Gossamer Bio
Mar 7, 2023
Downgrades: Market Perform
Price Target: $5
Current: $2.28
Upside: +119.30%
AnaptysBio
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $47.41
Upside: -
Rocket Pharmaceuticals
Jul 8, 2022
Initiates: Outperform
Price Target: $22
Current: $3.48
Upside: +532.18%
Apellis Pharmaceuticals
Mar 1, 2022
Maintains: Strong Buy
Price Target: $112 → $114
Current: $22.58
Upside: +404.87%
Crescent Biopharma
Nov 15, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $9.59
Upside: -